Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | ALPL | P05186 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | SCN1A | P35498 | 1/20 | 0.45 |
| ▸ | SCN4A | P35499 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.45 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10802626 | 0.86 | APAF1 (0.48) | ALDH1A1ALPLTP53ITGA4SCN9A | |
| SCHEMBL4255735 | 0.86 | TP53 (0.52) | ALDH1A1TP53SCN9ACNR1MAPT | |
| SCHEMBL4257897 | 0.85 | MAPT (0.40) | ALDH1A1ALPLTP53ITGA4NPSR1 | |
| SCHEMBL10954920 | 0.85 | ALPL (0.41) | ALDH1A1ALPLTP53ITGA4SCN9A | |
| SCHEMBL11045654 | 0.85 | TP53 (0.54) | ALDH1A1ALPLTP53CNR1MAPT | |
| SCHEMBL4259885 | 0.85 | ADAMTS5 (0.52) | ALDH1A1TP53NPSR1CNR1MAPT | |
| SCHEMBL4260419 | 0.85 | PARK7 (0.51) | ALDH1A1ALPLCNR1 | |
| SCHEMBL4172070 | 0.84 | SCN9A (0.44) | ALDH1A1ALPLTP53ITGA4SCN9A | |
| SCHEMBL10955719 | 0.84 | SCN9A (0.41) | ALDH1A1ALPLTP53ITGA4SCN9A | |
| SCHEMBL4164003 | 0.82 | ITGA4 (0.45) | ALDH1A1ITGA4MAPTCACNA1FCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | claimed |
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | disclosed |
| US-4490381-A | HYPOGLYCEMIC AND ANTIDIABETIC AGENTS, ALSO ALDOSE REDUCTASE INHIBIIOTRS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-12-25 | — | — | US | disclosed |
| EP-0028906-B1 | 1'-SUBSTITUTED-SPIRO(IMIDAZOLIDINE-4,3'-INDOLINE)-2,2',5-TRIONES, PROCESSES FOR THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS THEREOF | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-10-03 | — | — | EP | disclosed |
| US-4386100-A | COMPLICATIONS OF DIABETES OR GALACTOSEMIA | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-05-31 | — | — | US | disclosed |
| EP-0066378-A1 | Pharmaceutical spiro-hydantoin derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-12-08 | — | — | EP | disclosed |
| EP-0028906-A1 | 1'-Substituted-spiro(imidazolidine-4,3'-indoline)-2,2',5-triones, processes for their manufacture and pharmaceutical compositions thereof | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | TRPV1, TRPV2, TRPV3 | ALDH1A1 502/4885ALPL 4176/4885TP53 3194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.